Skip to main content

Steris PLC (STE)

NYSE: STE · IEX Real-Time Price · USD
225.09 0.90 (0.40%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap22.40B
Revenue (ttm)3.41B
Net Income (ttm)287.40M
Shares Out99.76M
EPS (ttm)3.28
PE Ratio68.67
Forward PE34.25
Dividend$1.60 (0.71%)
Ex-Dividend DateSep 2, 2021
Volume340,469
Open225.13
Previous Close224.19
Day's Range222.75 - 225.66
52-Week Range169.67 - 225.66
Beta0.57
AnalystsBuy
Price Target249.60 (+10.9%)
Est. Earnings DateNov 8, 2021

About STE

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solut...

IndustryHealth Care Equipment & Supplies
IPO DateJun 1, 1992
CEOWalter Rosebrough
Employees13,000
Stock ExchangeNYSE
Ticker SymbolSTE
Full Company Profile

Financial Performance

In 2020, Steris's revenue was $3.11 billion, an increase of 2.53% compared to the previous year's $3.03 billion. Earnings were $397.40 million, a decrease of -2.52%.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for Steris stock is "Buy." The 12-month stock price forecast is 249.60, which is an increase of 10.89% from the latest price.

Price Target
$249.60
(10.89% upside)
Analyst Consensus: Buy

News

Here's Why You Should Add STERIS (STE) to Your Portfolio

Investors are optimistic about STERIS (STE) owing to elevated consumer demand and rebound in procedure volumes and raised 2022 outlook.

1 week ago - Zacks Investment Research

2 Top Healthcare Stocks to Buy for the Long Haul

Their enduring appeal is nothing to pass over.

Other symbols:INMD
1 week ago - The Motley Fool

Steris (STE) Upgraded to Buy: What Does It Mean for the Stock?

Steris (STE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 weeks ago - Zacks Investment Research

Steris (STE) Down 1.5% Since Last Earnings Report: Can It Rebound?

Steris (STE) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Here's Why You Should Add STERIS (STE) to Your Portfolio Now

STERIS (STE) ended first-quarter fiscal 2022 with better-than-expected results and strong segmental performance, driving the top line.

1 month ago - Zacks Investment Research

STERIS (STE) Q1 Earnings Beat Estimates, 2022 Guidance Up

STERIS (STE) reported better-than-expected revenues for first-quarter fiscal 2022 on strong segmental performance driving the top line.

2 months ago - Zacks Investment Research

Steris (STE) Q1 Earnings and Revenues Top Estimates

Steris (STE) delivered earnings and revenue surprises of 17.33% and 7.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

STERIS Announces Financial Results for Fiscal 2022 First Quarter

DUBLIN, IRELAND, Aug. 09, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 first quarter ended June 30, 2021. Revenue as ...

2 months ago - GlobeNewsWire

5 Top Buy-Rated Stocks With Dividend Hikes Expected This Week

After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends that help to provide an income stream.

Other symbols:BCEIBRMLMTSN
2 months ago - 24/7 Wall Street

STERIS (STE) to Report Q1 Earnings: What's in the Cards?

Acquisitions of Cantel Medical and Key Surgical are expected to have contributed significantly to STERIS' (STE) first-quarter revenues.

2 months ago - Zacks Investment Research

STERIS to Host a Conference Call for Fiscal 2022 First Quarter Financial Results on August 10, 2021

DUBLIN, IRELAND , July 27, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2022 first quarter financ...

2 months ago - GlobeNewsWire

Steris (STE) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Here's Why You Should Add STERIS (STE) to Your Portfolio

Investors are optimistic about STERIS (STE) owing to strong segmental performance and bullish 2022 outlook.

3 months ago - Zacks Investment Research

Five-Year Compounded Value of Steris Holdings

In a world obsessed with price movements of stocks, it's easy to lose sight of what those prices represent -- the value of holding a company's future profit potential. One of the key ways that profit po...

3 months ago - Benzinga

Steris (STE) Up 5% Since Last Earnings Report: Can It Continue?

Steris (STE) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

STERIS (STE) Expands Product Suite With New Acquisition

STERIS' (STE) acquisition of Cantel Medical will complement and broaden the former's product and service offerings, global reach and customers.

4 months ago - Zacks Investment Research

STERIS Completes the Acquisition of Cantel Medical

DUBLIN, IRELAND, June 02, 2021 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that it has completed the previously announced acquisition of Cantel Medical, a glo...

4 months ago - GlobeNewsWire

Crocs Set to Join S&P MidCap 400 and Organogenesis to Join S&P SmallCap 600

NEW YORK, May 26, 2021 /PRNewswire/ -- S&P SmallCap 600 constituent Crocs Inc. (NASD:CROX) will replace Cantel Medical Corp. (NYSE:CMD) in the S&P MidCap 400, and Organogenesis Holdings Inc. (NASD: ORGO...

Other symbols:SPGI
4 months ago - PRNewsWire

STERIS (STE) Q4 Earnings Fall Shy of Estimates, FY22 View Up

STERIS' (STE) fourth-quarter 2021 revenues improved year over year on robust growth across three segments.

4 months ago - Zacks Investment Research

Recap: Steris Q4 Earnings

Shares of Steris (NYSE:STE) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 0.61% over the past year to $1.63, which missed the estimat...

4 months ago - Benzinga

STERIS Announces Financial Results for Fiscal 2021 Fourth Quarter and Full Year

DUBLIN, IRELAND, May 18, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2021 fourth quarter ended March 31, 2021. Revenue as...

4 months ago - GlobeNewsWire

STERIS (STE) to Report Q4 Earnings: What's in the Cards?

STERIS (STE) is likely to have continued to gain from the robust demand of PPE and COVID-19-related products in Q4.

5 months ago - Zacks Investment Research

STERIS Announces Changes to Board of Directors

DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced...

5 months ago - GlobeNewsWire

STERIS to Host a Conference Call for Fiscal 2021 Fourth Quarter and Full Year Financial Results on May 19, 2021

DUBLIN, IRELAND, April 27, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 fourth quarter and f...

5 months ago - GlobeNewsWire

STERIS (STE) Hits a New 52-Week High: What's Driving It?

Investors are optimistic about STERIS (STE) backed by elevated consumer demand and strong segmental growth in third-quarter fiscal 2021.

5 months ago - Zacks Investment Research